XLO
Xilio Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.03
+3.35%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 1.57x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 0.73x
- Price / sales
- 0.82x
- Price / cash flow
- -0.87x
Enterprise value
- Enterprise value
- -$76.9M
- EV / sales
- -1.20x
- EV / EBITDA
- 3.75x
- EV / EBIT
- 2.45x
- Market cap
- $52.8M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026